Literature DB >> 21785977

Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice.

Michael R Hunsaker1, Claudia M Greco, Marian A Spath, Arie P T Smits, Celestine S Navarro, Flora Tassone, Johan M Kros, Lies-Anne Severijnen, Elizabeth M Berry-Kravis, Robert F Berman, Paul J Hagerman, Rob Willemsen, Randi J Hagerman, Renate K Hukema.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder generally presenting with intention tremor and gait ataxia, but with a growing list of co-morbid medical conditions including hypothyroidism, hypertension, peripheral neuropathy, and cognitive decline. The pathological hallmark of FXTAS is the presence of intranuclear inclusions in both neurons and astroglia. However, it is unknown to what extent such inclusions are present outside the central nervous system (CNS). To address this issue, we surveyed non-CNS organs in ten human cases with FXTAS and in a CGG repeat knock-in (CGG KI) mouse model known to possess neuronal and astroglial inclusions. We find inclusions in multiple tissues from FXTAS cases and CGG KI mice, including pancreas, thyroid, adrenal gland, gastrointestinal, pituitary gland, pineal gland, heart, and mitral valve, as well as throughout the associated autonomic ganglia. Inclusions were observed in the testes, epididymis, and kidney of FXTAS cases, but were not observed in mice. These observations demonstrate extensive involvement of the peripheral nervous system and systemic organs. The finding of intranuclear inclusions in non-CNS somatic organ systems, throughout the PNS, and in the enteric nervous system of both FXTAS cases as well as CGG KI mice suggests that these tissues may serve as potential sites to evaluate early intervention strategies or be used as diagnostic factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785977      PMCID: PMC3222079          DOI: 10.1007/s00401-011-0860-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  75 in total

1.  Magnetic resonance imaging study in older fragile X premutation male carriers.

Authors:  Danuta Z Loesch; Lucas Litewka; Peter Brotchie; Richard M Huggins; Flora Tassone; Mark Cook
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

2.  Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.

Authors:  James A Bourgeois; Faraz Farzin; James A Brunberg; Flora Tassone; Paul Hagerman; Lin Zhang; David Hessl; Randi Hagerman
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

3.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

4.  Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study.

Authors:  Elan Louis; Carol Moskowitz; Michael Friez; Maria Amaya; Jean Paul G Vonsattel
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

5.  Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  C M Greco; R F Berman; R M Martin; F Tassone; P H Schwartz; A Chang; B D Trapp; C Iwahashi; J Brunberg; J Grigsby; D Hessl; E J Becker; J Papazian; M A Leehey; R J Hagerman; P J Hagerman
Journal:  Brain       Date:  2005-12-05       Impact factor: 13.501

6.  Protein composition of the intranuclear inclusions of FXTAS.

Authors:  C K Iwahashi; D H Yasui; H-J An; C M Greco; F Tassone; K Nannen; B Babineau; C B Lebrilla; R J Hagerman; P J Hagerman
Journal:  Brain       Date:  2005-10-24       Impact factor: 13.501

7.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

8.  Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Debby Van Dam; Vanessa Errijgers; R Frank Kooy; Rob Willemsen; Edwin Mientjes; Ben A Oostra; Peter Paul De Deyn
Journal:  Behav Brain Res       Date:  2005-07-30       Impact factor: 3.332

9.  Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation.

Authors:  Elizabeth Berry-Kravis; Kristina Potanos; Dahlia Weinberg; Lili Zhou; Christopher G Goetz
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

Review 10.  Autonomic failure in neurodegenerative disorders.

Authors:  Horacio Kaufmann; Italo Biaggioni
Journal:  Semin Neurol       Date:  2003-12       Impact factor: 3.420

View more
  58 in total

1.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

Review 2.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 4.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

5.  Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation.

Authors:  A Schneider; C Johnston; F Tassone; S Sansone; R J Hagerman; E Ferrer; S M Rivera; D Hessl
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 6.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

7.  FXTAS: size does matter!

Authors:  Chantal Sellier; Nicolas Charlet-Berguerand
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

10.  Immune-mediated disorders among women carriers of fragile X premutation alleles.

Authors:  Tri Indah Winarni; Weerasak Chonchaiya; Tanjung Ayu Sumekar; Paul Ashwood; Guadalupe Mendoza Morales; Flora Tassone; Danh V Nguyen; Sultana M H Faradz; Judy Van de Water; Kylee Cook; Alyssa Hamlin; Yi Mu; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-08-17       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.